Kadcyla (ado-trastuzumab emtansine; T-DM1) outperformed Herceptin (trastuzumab) regarding overall survival (OS; time from treatment until death of any cause) and invasive disease-free survival (iDFS; ...

Kadcyla is approved in 113 countries and is the standard of care for people with HER2-positive eBC with residual invasive disease following neoadjuvant treatment, based on previous positive ...

Kadcyla is currently approved by the FDA for the treatment of patients with HER2-positive, metastatic breast cancer previously treated with a taxane and Herceptin. The approval was based on the phase ...

At three years, 88.3 percent of people treated with Kadcyla did not have their breast cancer return compared to 77.0 percent treated with Herceptin, an 11.3 percent improvement.

NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

FDA approved Roche%27s Kadcyla Drug is double-shot of medication New treatment OK%27d for patients with certain form of cancer WASHINGTON (AP) — The U.S. Food and Drug Administration has ...

BOSTON (CBS) - The FDA approval of the breast cancer drug Kadcyla is getting a welcome reception from a local oncologist. WBZ's Diane Stern spoke with Dr. Eric Winer, ...

Genentech has announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast ...

Kadcyla was granted priority review on November 2012. Genentech plans to launch Kadcyla soon. For more information call (781) 895-0600 or visit www.immunogen.com. Picked For You ...

ZURICH (Reuters) – Roche said on Wednesday its drug Kadcyla, a treatment for an aggressive form of breast cancer, had been approved in Europe following U.S. approval in February. Kadcyla trea… ...

Kadcyla is a wonder drug, keeping my lung tumours stable and healing the cancerous tumours in my spine to a point where there is No Evidence of Active Disease. I know others who've had similar ...

Genentech, a member of the Roche Group, announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer who ...